Turkey producers should not avoid using chemical anticoccidial products for fear of resistance, but they do need to use them strategically. In an appearance on the Iowa Turkey Federation’s Turkey Talkshow podcast, Steven Clark, DVM, Huvepharma’s veterinary technical services manager, said new evidence suggests there is “minimal risk” with common products, providing farmers rotate when necessary.
The USDA Center for Veterinary Biologics has granted Huvepharma approval for the manufacturing and sale of a new broiler-breeder coccidiosis vaccine, Advent P, which contains Eimeria necatrix and E. brunetti.
Commercial trials have demonstrated the efficacy of Avert® NE from Huvepharma against necrotic enteritis in commercial broiler facilities. David Smith, DVM, MS, director of poultry technical services at Huvepharma discussed these trials, which evaluated livability and zootechnical performance of birds given the vaccine, pointing to improvements in vaccinated flocks compared to unvaccinated birds.
Abstract: A field study of Clostridium perfringens enumeration methods in the broiler house environment
Abstract: A field study of Clostridium perfringens enumeration methods in the broiler house environment
Abstract: Evaluation of the development of resistance following prolonged use of synthetic anticoccidials in a high challenge floor pen model
When enteritis strikes, the challenge is identifying the exact cause. In February 2023, Huvepharma’s research and development personnel received a call about enteritis symptoms in two commercial antibiotic-free turkey houses. A team went out to conduct a thorough field investigation to determine precisely what was going on with the flocks.
Synthetic anticoccidials, also referred to as “chemicals,” are often considered the most efficacious tools to mitigate coccidiosis in poultry. Yet, despite their effectiveness, veterinarians and producers sometimes hesitate to incorporate them into control programs due to the concern of chemical-resistant Eimeria strains developing.
Avian metapneumovirus (aMPV) is now the leading health issue facing the US turkey industry, according to a recent survey of turkey industry professionals and veterinarians representing 73% of the 218 million birds raised in the US over 12 months ending August 2024.
The trend toward reducing or eliminating antimicrobial use in broiler production has led to an increased incidence of necrotic enteritis, resulting in the need for alternative intervention strategies, such as vaccination, to control NE.
Virtually everyone in the poultry industry is aware of coccidiosis — a disease caused by protozoan parasites, Eimeria, that develop within the intestine of most domestic and wild animals and birds. The condition is more elusive in turkeys, however.
Coccidiosis vaccination is a critical tool to mitigate economic losses for broiler producers. However, dry litter conditions and low placement densities can complicate successful vaccine replication and subsequent immunizing exposure.
USDA’s Center for Veterinary Biologics has granted Huvepharma a conditional license for the manufacturing and sale of a new turkey coccidiosis vaccine.
The parasitic disease coccidiosis remains one of the most economically significant diseases for turkeys. In 2023, coccidiosis ranked 10th in a US turkey industry survey of 38 health issues. Unfortunately, it often goes unnoticed.
Modern Poultry is pleased to host
this editorial page on behalf of
